Blood Cancer Portfolio
Chronic Lymphocytic Leukemia
Key Facts
About BeOne Medicines
BeOne Medicines is building the world's leading oncology company through scientific excellence and global reach, serving patients across 45+ countries with 12,000+ employees. The company has successfully transitioned from development to commercialization with approved therapies generating significant revenue. With substantial U.S. investment including $750M in R&D and a 400,000 square foot manufacturing facility, BeOne is positioned as a major player in global cancer treatment.
View full company profileAbout BeOne Medicines
BeOne Medicines is building the world's leading oncology company through scientific excellence and global reach, serving patients across 45+ countries with 12,000+ employees. The company has successfully transitioned from development to commercialization with approved therapies generating significant revenue. With substantial U.S. investment including $750M in R&D and a 400,000 square foot manufacturing facility, BeOne is positioned as a major player in global cancer treatment.
View full company profileTherapeutic Areas
Other Chronic Lymphocytic Leukemia Drugs
| Drug | Company | Phase |
|---|---|---|
| Arzerra (ofatumumab) | Genmab | Approved |
| ONO-4059 (tirabrutinib) | Ono Pharmaceutical | Phase 3 |